Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility. Other Scholarly Work

Beitsch, Peter D, Whitworth, Pat W, Hughes, Kevin S et al. (2019). Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer: Untapped clinical utility and PARP inhibitor trial eligibility. . JOURNAL OF CLINICAL ONCOLOGY, 37(15), 10.1200/JCO.2019.37.15_suppl.1583

Industry Collaboration

cited authors

  • Beitsch, Peter D; Whitworth, Pat W; Hughes, Kevin S; Patel, Rakesh; Baron, Paul; Rosen, Barry; Grady, Ian; Holmes, Dennis; Simmons, Rache M; Smith, Linda Ann; Compagnoni, Gia; Coomer, Cynara L; Brown, Eric Allen; Barbosa, Karen; Clark, Patricia; Gold, Linsey P; Riley, Lee B; Esplin, Edward D; Yang, Shan; Nussbaum, Robert L

authors

publication date

  • May 20, 2019

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • IL, Chicago

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 37

issue

  • 15